Tilray's Revenue Growth Masks Core Weakness; WAIT Rating Reaffirmed but Downside Risk Rises
Read source articleWhat happened
Tilray's recent record revenue was inflated by acquisition contributions, while legacy cannabis sales fell 13% and the company slipped back to an operating loss. The Motley Fool article raises the question of whether the stock at its record low is a value trap, and the underlying data support caution: beverage revenue and margins deteriorated sharply, international cannabis growth remains the main bright spot. Management’s adjusted EBITDA of $8.4 million in Q2 FY26 remains heavily dependent on non-cash add-backs, and cash from operations was negative $8.5 million, though the company holds a modest net cash position. The enacted U.S. hemp-derived THC cap effective November 2026 threatens one of Tilray’s touted growth vectors, while Schedule III rescheduling timing remains uncertain. This combination leaves the risk/reward finely balanced but tilting toward downside unless upcoming quarters show clear improvement in cash generation and margin durability.
Implication
Given the deterioration in core cannabis and beverage profitability, the current price does not offer an attractive margin of safety relative to the risk of further share-price declines. The near-term catalysts of Q3 FY26 results and regulatory updates will be critical; if adjusted EBITDA fails to improve sequentially or if cash flow worsens, the bear case becomes more likely. The reversal to operating loss despite record revenue underscores that growth is being bought via acquisitions rather than generated organically, which dilutes long-term value. While the net cash position provides some liquidity buffer, the reliance on equity issuance and the potential elimination of hemp-THC beverages under the new federal cap could pressure the shares further. Therefore, maintain a WAIT rating and consider only opportunistic entries near $7 if evidence emerges that international cannabis can offset domestic weaknesses.
Thesis delta
The new information from the Motley Fool article highlights that recent revenue growth is acquisition-driven and that core cannabis sales are declining, which slightly increases the probability of the bear scenario in our framework. The operating loss return reinforces our existing caution about relying on non-cash add-backs for adjusted EBITDA and questions the sustainability of current profitability. As a result, we lower our conviction in the bull case and maintain the WAIT rating, with a slightly lower attractive entry threshold pending Q3 FY26 results.
Confidence
High